Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

BACKGROUND: MAPK activation and mTOR-dependent signaling are hallmarks of glioblastoma. We conducted a phase I-II study of sorafenib (an inhibitor of Raf-kinase and VEGFR-2) and the mTOR inhibitor temsirolimus in recurrent glioblastoma. METHODS: Patients with recurrent glioblastoma progressing follo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Schiff, David, Jaeckle, Kurt A, Anderson, S. Keith, Galanis, Evanthia, Giannini, Caterina, Buckner, Jan C., Stella, Phillip, Flynn, Patrick J, Erickson, Bradley J, Schwerkoske, John F, Kaluza, Vesna, Twohy, Erin, Dancey, Janet, Wright, John, Sarkaria, Jann N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867230/
https://ncbi.nlm.nih.gov/pubmed/29313954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31219
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados